Compare AIRE & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | CALC |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | AIRE | CALC |
|---|---|---|
| Price | $0.45 | $6.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 6.0M | 97.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,149,567.00 | N/A |
| Revenue This Year | $456.19 | N/A |
| Revenue Next Year | $105.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 994.18 | N/A |
| 52 Week Low | $0.14 | $1.42 |
| 52 Week High | $2.89 | $7.20 |
| Indicator | AIRE | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 71.29 |
| Support Level | $0.40 | $5.55 |
| Resistance Level | $0.60 | $7.20 |
| Average True Range (ATR) | 0.05 | 0.69 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 25.72 | 86.15 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.